Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 vs TPC in HR+/HER2- Breast Cancer
NCT07461454Phase 3Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of YL202 in breast cancer (2 arms), sponsored by MediLink Therapeutics. Primary endpoint: Progression-Free Survival at 18 months. Started Mar 2026; status: recruiting.
02
Drugs
YL202
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07461454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461454.